Int Neurourol J.  2016 Nov;20(Suppl 2):S120-S130. 10.5213/inj.1632724.362.

How Precisely Can Prostate Cancer Be Managed?

• Zhuang L
• Johnson MT

• KMID: 2362505
• DOI: http://doi.org/10.5213/inj.1632724.362

Abstract

Progress has been made in applying genetic information to disease management in the postgenomic era, and precision medicine is emerging in prostate cancer management. The prostate health index, the 4-kallikrein (4K) score, and the PCA3, TMPRSS2-ERG, and Prostarix tests have potential for refining prostate cancer screening in conjunction with traditional prostate-specific antigen testing. The Confirm MDx and PCA3 tests have shown promise in identifying men who need be rebiopsied after a primary negative biopsy. Oncotype DX, Prolaris, the biopsy-based Decipher prostate cancer test, and ProMark may improve predictive risk stratification in addition to the traditional Gleason score and tumor stage. Decipher and Prolaris may predict biochemical recurrence and metastasis after radical prostatectomy and possibly help identify patients who need adjuvant therapy. Androgen receptor splice variant 7 appears effective in guiding the selection of second hormonal manipulation with abiraterone or enzalutamide versus chemotherapy when treating metastatic castration-resistant prostate cancer.

Keyword

Prostatic Neoplasms; Precision Medicine; Biomarkers; Receptors, Androgen

MeSH Terms

Biomarkers
Biopsy
Disease Management
Drug Therapy
Humans
Male
Mass Screening
Neoplasm Grading
Neoplasm Metastasis
Precision Medicine
Prostate*
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms*
Receptors, Androgen
Recurrence
Biomarkers
Prostate-Specific Antigen
Receptors, Androgen